抗因特鲁金-17药物用于成功治疗性牛皮
Prisca Guerra1, Elia Rosi1, Ilaria Scandagli1
1Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.
Cytokine
|September 6, 2023
概括
干白素-17 (IL-17) 抑制剂对治疗罕见的性牛皮亚型,如通用性性牛皮 (GPP) 和Hallopeau (ACH) 持续性皮炎 (ACH) 的治疗有希望. 这项研究强调了它们在三名患者的成功使用,提供了潜在的新治疗途径.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
背景情况:
- 泛性性牛皮 (GPP) 和Hallopeau (ACH) 的持续性皮炎是罕见的,严重的性牛皮 (PP) 形式.
- 这些疾病缺乏标准化的治疗指南和强大的临床试验,这给治疗带来了挑战.
- 洲际蛋白-17 (IL-17) 参与了各种炎症性皮肤疾病的发病,包括PP.
研究的目的:
- 报告IL-17抑制剂在治疗罕见PP亚型的成功利用情况.
- 审查目前对IL-17在PP病变发生中的作用的理解.
- 评估IL-17抑制剂作为PP治疗选择的疗效.
主要方法:
- 追溯三名罕见PP亚型患者用IL-17抑制剂治疗的病例系列.
- 对PP中的IL-17及其向疗法的现有文献的审查.
- 对治疗反应和不良事件的临床评估.
主要成果:
- 这三个患有罕见PP亚型的患者都经历了IL-17抑制剂的成功治疗结果.
- 在这个队列中,IL-17抑制表现出了有利的安全性.
- 这些发现表明,IL-17抑制剂在不同的PP频谱疾病中具有潜在的治疗益处.
结论:
- 抗IL-17疗法对患有GPP和ACH的患者来说是一个有希望和有效的治疗选择.
- 需要进行进一步的研究和临床试验,以确定IL-17抑制剂在罕见的PP亚型中使用的最终指南.
- 针对IL-17通路提供了一种有价值的治疗策略,用于管理具有挑战性的性牛皮病状况.
相关概念视频
T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
149
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
149
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
Drugs Used in Lower Respiratory Disorders: Overview
487
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
487


